Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells

BIOLOGICAL2 trials

Sponsors

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

Conditions

Clinical TrialClinical TrialsEfficacyHuman Motor Neuron ProgenitorInduced Pluripotent Stem CellsRCTSafetySpinal Cord Injury

Phase 1

Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial

RecruitingNCT06976229

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.Clinical Trials, Efficacy, Human Motor Neuron Progenitor +4

Start: 2025-07-02End: 2028-05-30Target: 12Updated: 2025-11-25

Phase 2

Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial

Not yet recruitingNCT06974968

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.Clinical Trial, Efficacy, Human Motor Neuron Progenitor +5

Start: 2028-05-25End: 2031-05-26Target: 60Updated: 2025-11-25

Related Papers

Safety and early efficacy of iPSC-derived motor neuron progenitor cells in subacute spinal cord injury: protocol for a phase I, multicentre, open-label, single-arm trial.

2026-07-08